Sphingosine kinases (SK) catalyze the formation of sphingosine-1-phosphate (S1P) which plays a crucial role in cell growth and survival. Here, we show that prolactin (PRL) biphasically activates the SK-1, but not the SK-2 subtype, in the breast adenocarcinoma cell-line MCF7. A first peak occurs after minutes of stimulation and is followed by a second delayed activation after hours of stimulation. A similar biphasic effect on SK-1 activity is seen for 17b-estradiol (E 2 ). The delayed activation of SK-1 derives from an upregulated mRNA and protein expression and is due to increased SK-1 promoter activity and mechanistically involves STAT5 activation as well as protein kinase C and the classical mitogen-activated protein kinases. Furthermore, glucocorticoids also block both hormone-induced SK-1 expression and activity. Functionally, long-term stimulation of MCF7 cells with PRL or E 2 is well known to trigger increased cell proliferation and migration. Both hormone-induced cell responses critically involve SK-1 activation since the depletion of SK-1, but not SK-2, by siRNA transfection abolishes the hormone-induced cell proliferation and migration. In summary, our data show that PRL and E 2 cause a pronounced delayed SK-1 activation which is due to increased gene transcription, and critically determines the capability of cells to grow and move. Thus, the SK-1 may represent a novel attractive target for anti-tumor therapy.
Introduction
Sphingosine-1-phosphate (S1P) has turned out to be a bioactive lipid critically involved in various cell responses such as cell proliferation and differentiation, survival, and migration (Huwiler et al. 2000 , Spiegel & Milstien 2003 , Hait et al. 2006 . Although S1P may exert its effects via both intracellular and extracellular actions and targets, most of the so-far-described cellular responses triggered by S1P are mediated through specific cell surface S1P receptors, the S1P 1-5 receptors, which belong to the class of G-protein-coupled receptors (Hla 2003) . S1P is produced by sphingosine kinases (SKs) which can be activated by a variety of stimuli that couple either to receptor tyrosine kinases like the platelet-derived and epidermal growth factors (EGFs) or to various G-proteincoupled receptors (Alemany et al. 2000 , Huwiler et al. 2006 . To date, two SK subtypes have been cloned and partially characterized, SK-1 and SK-2 (Kohama et al. 1998 , Liu et al. 2000 . SK-1 was suggested to be involved in certain forms of cancer , whereas SK-2 is speculated to contribute to immunological responses (Baumruker et al. 2005) . Thus, overexpression of SK-1 leads to a transformed phenotype of NIH 3T3 fibroblasts causing foci formation, colony growth in soft agar, and tumor formation in SCID mice (Xia et al. 2000) . In addition, overexpression of SK-1 in MCF7 breast cancer cells causes enhanced proliferation, decreased apoptosis, and leads to larger tumors in nude mice in an estrogen-dependent manner (Nava et al. 2002 , Sukocheva et al. 2003 . Moreover, several tumor types showed an overexpression of SK-1 when compared with normal tissue (French et al. 2003) . All these data strongly suggest a critical contribution of SK-1 in tumor development and growth.
The involvement of the mammogenic hormones prolactin (PRL) and 17b-estradiol (E 2 ) in normal mammary growth and development is well documented (Couse & Korach 1999 , Ormandy et al. 2003 and it has been suggested that these hormones may also contribute to the development and progression of breast cancer. E 2 has been clearly defined as a mammary mitogen, and anti-estrogen therapy is the most successful treatment for patients with estrogen receptor a (ERa) positive breast tumors (Jordan 2004) . But this therapy is restricted mainly because of a wide range of side effects of E 2 on bone, brain, cardiovascular, and other targeted tissues. Thus, understanding the signaling pathways that couple mammogenic hormones like PRL and E 2 to a specific cellular function has become a primary focus of inquiry.
In this study, we investigated the contribution of SKs in PRL-and E 2 -mediated cell responses in the breast cancer cell line MCF7. We show for the first time that PRL is able to induce a prolonged SK-1, but not SK-2, enzymatic activity which is due to a stimulation of the SK-1 promoter activity causing increased mRNA and protein expression.
Furthermore, cell proliferation and migration, which are both triggered by PRL and E 2 and are critical for tumor development, strongly depend on SK-1 activity since cellular depletion of SK-1 by siRNA transfection abolishes both cell responses.
Materials and methods

Chemicals
[ 32 P]ATP (specific activity, O5000 Ci/mmol) was from GE Health Care; dexamethasone, PRL, E 2 , and 4,6-diamino-2-phenylindole (DAPI) were from Sigma-Aldrich Fine Chemicals; staurosporine and Ro 31-8220 were from Biomol, Hamburg, Germany; U0126 was from Merck Bioscience; monoclonal STAT5a/b antibody was from BD Biosciences, Heidelberg, Germany; siRNA of human STAT5 (sc-29495) was from Santa Cruz, Heidelberg, Germany; OligofectAMINE and all cell culture nutrients were from Invitrogen.
Cell culturing and siRNA transfections MCF7 cells were cultured as previously reported (Döll et al. 2005) , and gene silencing of SKs was conducted exactly as described (Huwiler et al. 2006) .
Western blot analysis
Confluent MCF7 were stimulated for the indicated time periods in phenol red-free Dulbecco's modified Eagle medium (DMEM) containing 0.1 mg/ml fatty acid-free BSA. Protein extracts were prepared exactly as previously described (Döll et al. 2005) . About 30 mg protein were separated by SDS-PAGE, transferred to nitrocellulose membrane, and Western blot analysis was performed as previously described using a polyclonal anti-peptide antibody against human SK-1 at a dilution of 1:2000 (Döll et al. 2005) .
Quantitative real-time PCR (TAQMAN) About 1.0 mg total RNA isolated with TRIZOL reagent was used for reverse transcriptase-PCR (First strand synthesis kit, MBI) utilizing an oligo(dT) 18 primer for amplification. The real-time PCR was carried out in ABgene plates. Probes and primers for human SK-1, SK-2, and GAPDH were obtained from Applied Biosystems, Darmstadt Germany. The reporter dyes chosen were 6-FAM/Tamra and VIC/Tamra. The PCR buffer used in the experiments was from ABgene. After cDNA synthesis, 100 ng was used for further analysis. The run was performed on the Applied Biosystems 7700 HT sequence detection system. The cycling conditions were as following: 95 8C for 15 min (1 cycle), 95 8C for 15 s, and 60 8C for 1 min (40 cycles). SDS version 1.9.1 software (ABI Prism, Applied Biosystems) was used to analyze real-time and endpoint fluorescence.
Promoter studies
A 2217 bp fragment of the human SK-1 promoter was cloned by RT-PCR using the following primers: forward with a BglII side: 5 0 -gaagatctcaccaaagtccctcgctggag-3 0 ;
reverse with a HindIII side: 5 0 -gggaagcttttctgggagaggatccctg-3 0 . A 1053 bp SK-1 promoter fragment was cloned by RT-PCR using the same reverse primer and the forward primer: 5 0 -gaagatctgcttggctttccaatcccgac-3 0 . A 619 bp SK-1 promoter fragment was cloned by RT-PCR using the same reverse primer and the forward primer:
The promoter fragments were fused into the pGL3 basic luciferase reporter gene-containing vector (Promega). To measure SK-1 promoter activity, a luciferase reporter gene assay was performed exactly as previously described (Huwiler et al. 2006 ) using a Lumat LB9507 luminometer (Berthold Detection Systems, Pforzheim, Germany). SK activity assay SK-1 activity was measured exactly as previously described (Döll et al. 2005 , Huwiler et al. 2006 . In brief, 30 mg protein extracts and 10 ml of 1 mM sphingosine (dissolved in 1 mg/ml BSA) were mixed with SK-1 buffer (20 mM Tris, pH 7.4, 20% glycerol, 1 mM mercaptoethanol, 1 mM EDTA, 1 mM sodium orthovanadate, 40 mM b-glycerophosphate, 15 mM NaF, 10 mg/ml leupeptin, 10 mg/ml aprotinin, 10 mg/ ml soybean trypsin inhibitor, 1 mM phenylmethylsulfonyl fluoride) in a total volume of 190 ml. For SK-1 activity, 0.5% Triton X 100 was included to block SK-2 activity (Liu et al. 2000) . For SK-2 activity, 1 M KCl was included to block SK-1 activity (Liu et al. 2000) . Reactions were started by addition of 10 ml [g-32 P]ATP (10 mCi, 20 mM) in 200 mM MgCl 2 and incubated for 15 min at 37 8C. Reactions were terminated by addition of 20 ml 1 N HCl followed by 800 ml chloroform/methanol/HCl (100/200/1, v/v), 240 ml chloroform and 240 ml of 2 M KCl followed by vigorous vortexing. After phase separation, 50 ml of the lipids in the organic lower phase were resolved by thin layer chromatography with 1-butanol/ethanol/ acetic acid/water (80:20:10:20, v/v) . Spots corresponding to S1P were analyzed and quantified using an Imaging System (Fujifilm Europe, Dü ssel dorf, Germany).
Migration assay
Chemotaxis was measured in Nunc cell culture inserts (polycarbonate membrane, 10 mm, 8.0 mm pore size) exactly as described (Döll et al. 2005) .
Proliferation assay
Transfected cells were starved for 24 h with serum-free DMEM. Proliferation of cells was assessed using 1 mCi/ml [ 3 H]methyl-thymidine in the absence of serum for the last 4 h of stimulation. After 24 h of stimulation, cells were washed twice with PBS and incubated in 5% trichloroacetic acid at 4 8C for 30 min, and the DNA was solubilized in 0.5 M NaOH for 30 min at 37 8C. Finally, [
3 H]thymidine incorporation was determined in a b-counter.
Statistical analysis
Statistical analysis was performed by one-way ANOVA. For multiple comparisons with the same control group, the limit of significance was divided by the number of comparisons according to Bonferroni. 
Results
Stimulation of MCF7 cells with PRL leads to a biphasic increase in SK activity. A first peak of activation occurs after 15 min of stimulation (Fig. 1A ) which declines again after 30 min. A second peak of activity is observed after 1 h of stimulation reaching a plateau after 24 h and stays elevated for at least 48 h the latest time point measured (Fig. 1B) . The delayed activation of SK-1 by PRL after 16 h is only slightly seen at 50 ng/ml of concentration but is more pronounced at 100 ng/ml and reaches maximal values at 1 mg/ml PRL ( Fig. 2A) . Another mammogenic hormone E 2 is also able to induce a similar biphasic activation of SK-1 in MCF7 cells (Fig. 1C and D) which confirms previous data of Sukocheva et al. (2003 Sukocheva et al. ( , 2006 . Dose-dependency experiments reveal a maximal effect on SK-1 activity after 16 h already at the low concentration of 10 nM E 2 (Fig. 2B) . In contrast, SK-2 activity, which was assayed under conditions where SK-1 is inhibited, i.e. by including 1 M KCl (Liu et al. 2000) , is not activated by PRL or E 2 ( Fig. 2A and B, open symbols).
To see whether the second delayed phase of SK activation depends on increased SK-1 protein expression, Western blot analyses were performed, using a specific antibody against SK-1 which was previously characterized (Döll et al. 2005 , Huwiler et al. 2006 .
As seen in Fig. 3A , PRL stimulation of MCF7 cells leads to a dose-dependent increased expression of the 44 and 51 kDa form of SK-1 (Fig. 3A) . Similarly, E 2 also upregulates SK-1 protein expression (Fig. 3B ). To further characterize whether the enhanced SK1 activity and protein expression is preceded by an enhanced mRNA expression, quantitative real-time PCR was performed. As shown in Fig. 3C , SK-1 mRNA expression is dose-dependently enhanced by PRL and also by E 2 . In contrast, SK-2 mRNA expression is rather downregulated by hormone treatment.
The increased mRNA expression of SK-1 is owing to increased gene transcription as shown by SK-1 promoter studies. To this end, a long (2217 bp) and two shorter (1053 and 691 bp) fragments of the human SK-1 promoter were cloned according to Nakade et al. (2003) and fused to a luciferase-containing vector. Transfection of MCF7 cells with these fragments followed by PRL or E 2 stimulation reveals that only the long 2217 bp promoter fragment is able to increase luciferase activity, whereas the two shorter fragments are ineffective (Fig. 4) .
To further document that the delayed activation of SK-1 by PRL and E 2 is due to increased de novo protein synthesis, the general translation inhibitor cycloheximide (CHX) was applied. As seen in Fig. 5A , CHX completely abolishes the delayed activation of SK-1 by both PRL and E 2 . In contrast, CHX has no reducing effect of the short-term PRL-or E 2 -stimulated SK-1 activity (Fig. 5B) , whereas the MEK inhibitor U0126 completely abolishes the early SK-1 activation (Fig. 5B) , confirming previous reports that the rapid activation of SK-1 requires the classical mitogen-activated protein kinase (MAPK) cascade.
The mechanisms of delayed SK-1 activation were further characterized. The MEK inhibitor U0126 not only suppresses the early effect of PRL on SK-1 activity (Fig. 5B ), but also blocks the delayed effect (Fig. 6A) . Similarly, the potent but unspecific protein kinase C (PKC) inhibitor staurosporine and the highly specific PKC inhibitor Ro 31-8220 completely abolish the effect of PRL on SK-1 activity (Fig. 6A ). All these inhibitors that reduced SK-1 activity also downregulated SK-1 mRNA expression (data not shown). Similarly, E 2 -stimulated delayed SK-1 activity also involves PKC and the classical MAPKs (Fig. 6B) .
Furthermore, since PRL has previously been reported to activate the Janus kinase (JAK)-STAT pathway especially involving STAT5 (Liu et al. 1995 , Hynes et al. 1997 , the involvement of STAT5 in SK-1 activation was investigated by depleting STAT5 by siRNA transfection. As seen in Fig. 7A inset, the STAT5 siRNA completely blocks STAT5 protein expression. Under this STAT5-depleted condition, PRL-triggered delayed SK-1 activity is abolished, suggesting that STAT5 is a critical transcription factor involved in PRL-stimulated delayed SK-1 upregulation. In contrast, depletion of STAT5 has no effect on the acute activation of SK-1 (Fig. 7B) .
Interestingly, the synthetic glucocorticoid dexamethasone also reduces both PRL-and E 2 -induced delayed SK-1 activity (Fig. 8 ) and mRNA expression (data not shown).
Increased proliferation and cell migration is not only characteristic for cancer cells but also normal breast epithelial cells are characterized by their ability to migrate and proliferate during the lactation cycle. To see whether SK-1 is involved in these cell responses, we depleted SK-1 from MCF7 cells by using the technique of siRNA transfection. As previously shown, transfection of MCF7 cells with siRNA targeted to SK-1 specifically reduced the expression of SK-1 without affecting SK-2 (Döll et al. 2005) . For MCF7 cells, both PRL and E 2 are well-established growth factors causing an increased [ 3 H]thymidine incorporation into newly synthesized DNA (Fig. 9) . However, when SK-1 was depleted from the cells, neither PRL nor E 2 triggered cell proliferation anymore (Fig. 9) , whereas neither a scrambled oligonucleotide nor siRNA of SK-2 affected the PRL-and E 2 -stimulated proliferation (Fig. 9) .
Finally, we measured the migratory capacity of MCF7 cells upon PRL and E 2 stimulation. As seen in Fig. 10 , Effect of prolactin and E 2 on SK-1 promoter activity in MCF7 cells. Subconfluent MCF7 cells were co-transfected with the wild-type 2217 bp SK-1 promoter DNA, a 1053 bp fragment, or a 691 bp fragment plus the plasmid coding for Renilla luciferase (pRL-CMV). After 24 h of transfection, cells were rendered serum-free and stimulated for 16 h with either vehicle (Co), prolactin (PRL, 5 mg/ml), or 17b-estradiol (E 2 , 1 mM). The ratio between beetle and Renilla luciferase activities was calculated and is depicted as relative luciferase activity (RLU). Data are meansGS.E.M. (nZ3), ***P!0.001 when compared with the vehicle-stimulated control value. (2007) 14 325-335 www.endocrinology-journals.org PRL and E 2 triggered a pronounced increase of cell migration. This effect is significantly reduced when depleting cells of SK-1, but not when using scrambled siRNA oligonucleotides or siRNA of SK-2. Additionally, CHX treatment abolishes both the PRL and E 2 effect on cell migration (Fig. 11A) , whereas the depletion of STAT5 from cells only abrogates the PRL effect, but not the E 2 effect on cell migration (Fig. 11B ).
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Discussion
In this study, we show for the first time that the mammogenic and lactogenic hormone PRL activates SK-1 in MCF7 breast cancer cells. PRL triggers a biphasic activation pattern of SK-1, i.e. a rapid and transient first peak and a second more delayed peak of activity occurring after 20 h and lasting up to 48 h. PRL is one important hormone required for mammary gland differentiation promoting morphological development and milk protein production in the lactating gland. Recent evidence has risen that PRL also plays a role in breast cancer development and growth (Tworoger & Hankinson 2006) . In rodents, PRL shows a clear tumor-promoting efficiency as transgenic female mice overexpressing the PRL gene spontaneously develop mammary carcinomas (RoseHellekant et al. 2003) , whereas in humans, the role of PRL in tumor formation and progression is less clear due to the failure of clinical trials evaluating the potential of functional PRL antagonists. Thus, although dopamine agonists (in vivo dopamine is the physiological negative regulator of PRL release from the anterior pituitary gland) drastically reduce circulating 
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www.endocrinology-journals.org PRL levels, no therapeutic benefit in breast cancer patients is seen by dopamine agonists (Bonneterre et al. 1988) .
Besides PRL, the SK-1 and its product S1P have also been proposed to play a critical role in tumor development and growth. Thus, S1P is a potent mitogen for many cell types (Huwiler et al. 2000 , Spiegel & Milstien 2003 . Furthermore, overexpression of SK-1 leads to a transformed phenotype of NIH 3T3 fibroblasts causing tumor formation in SCID mice (Xia et al. 2000) . In addition, overexpression of SK-1 in MCF7 breast cancer cells causes enhanced proliferation, decreased apoptosis, and leads to larger tumors in nude mice in an estrogen-dependent manner (Sukocheva et al. 2003) .
All these data made it very tempting to speculate on a relation between PRL and SK-1. The upregulation of SK-1 by PRL reported in this study was shown to mechanistically involve an activation of the SK-1 gene promoter (Fig. 4) . The human SK-1 promoter was first cloned by Nakade et al. (2003) and it was shown to be highly stimulated by the direct PKC activator TPA. The involvement of PKC in PRL-induced SK-1 upregulation is confirmed by the blocking effect of the selective PKC inhibitor Ro 318220 (Fig. 6A ). In agreement with these findings, Marte et al. (1994) reported that PRL signaling involves PKC-a activation Figure 7 Effect of STAT5 depletion by siRNA transfection on prolactin-induced SK-1 activity in MCF7 cells. MCF7 cells were transfected with either vehicle (control) or siRNA of human STAT5 as described in the Materials and methods section. Thereafter, cells were rendered serum-free and stimulated for 24 h with either vehicle (K) or 5 mg/ml prolactin (PRL, C) (A), or (B) for 15 min with vehicle (Co), 5 mg/ml prolactin (PRL) or 10 nM 17b-estradiol (E 2 ). Cell extracts were taken either for SDS-PAGE, protein transfer, and Western blot analysis of STAT5 (at a dilution of 1:250; inset) or for an SK-1 activity assay as described in the Materials and methods section. Effect of SK-1 and SK-2 depletion by siRNA transfections on prolactin and 17b-estradiol-induced proliferation of MCF7. MCF7 cells were either left untransfected (K) or transfected with 200 nM of a scrambled siRNA (Scr-siRNA), siRNA of human SK-1 (SK1-siRNA), or siRNA of human SK-2 (SK2-siRNA) as described in the Materials and methods section. Thereafter, cells were rendered serum-free for 48 h followed by a 24-h stimulation period with either vehicle (Co, open columns), prolactin (PRL; 5 mg/ml, hatched columns), or 17b-estradiol (E 2 ; 10 nM; closed columns). Cell proliferation was determined as described in the Materials and methods section. Data are meansGS.D. (nZ3), *P!0.05, **P!0.01, ***P!0.001 when compared with the respective unstimulated control values. (2007) 14 325-335 www.endocrinology-journals.org in the mouse mammary epithelial cells HC11. Similarly, Franklin et al. (2000) reported that PKC-a mediates PRL-stimulated aspartate aminotransferase expression in rat lateral prostate epithelial cells. On the other hand, Peters et al. (1999) reported that in a luteinized granulosa cell model, PRL receptor activation rather promotes activation of the PKC-d isoenzyme. Which PKC isoenzyme is finally involved in PRL-triggered SK-1 upregulation in MCF7 cells cannot be concluded unequivocally from our data. However, the fact that staurosporine, which shows a high selectivity for the Ca 2C -dependent PKC isoenzymes when compared with the Ca 2C -independent PKC isoenzymes (Meyer et al. 1989) , blocks PRLinduced SK-1 activity in the low nanomolar range (Fig. 6 ) rather favors the involvement of a Ca 2C -dependent PKC isoenzyme, i.e. PKC-a which is the only Ca 2C -dependent PKC isoenzyme expressed in MCF7 cells (Marino et al. 2001 ). An involvement of PKC-a in SK-1 mRNA upregulation and activation has also been shown for histamine-stimulated endothelial cells (Huwiler et al. 2006) ; thus, a general regulatory function of this PKC subtype in SK-1 expression may be envisioned.
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Recently, Perks et al. (2004) reported that in MCF7 cells, PRL acts as a survival factor and protects cells from ceramide-induced apoptosis. However, they could not find a proliferative effect of PRL in MCF7 cells which contrasts to other reports in the same cell system (Bernard et al. 1991 , Acosta et al. 2003 ; and our finding (Fig. 9) ) and in vivo (Chen et al. 2002) . Although the mechanism of this PRL-mediated cell protection was not further addressed, it is tempting to speculate that PRL stimulated S1P generation, which is a well-known anti-apoptotic factor and counterregulator of ceramide action (Hait et al. 2006) .
Similar to PRL, two other mammogenic factors also activate SK-1 in the same biphasic manner in MCF7 cells, i.e. E 2 (Sukocheva et al. 2003 (Sukocheva et al. , 2006 ; and this study) and EGF (Döll et al. 2005) . Interestingly, all three agonists act via different receptor classes. Whereas the PRL receptor (PRLR) belongs to the class of cytokine receptor superfamily and classically, but not exclusively couples to JAK/STAT, the EGF receptor belongs to the class of receptor tyrosine kinases and couples to various signaling devices including phospholipase C-g and PI3K. E 2 primarily acts through specific high-affinity ERs including a-and b-isoforms located within the cell nucleus. Although still controversial, many studies have shown an association of the PRLR with the ER receptor expression. Thus, PRLR and ERa are co-expressed in many breast tumors and PRL and E 2 can cross-regulate their receptors in breast cancer cells (Shafie & Brooks 1977 , Ormandy et al. 1997 , Gutzman et al. 2004a . Furthermore, it was reported that E 2 contributes to tumor development by trans-activating the EGF receptor via S1P generation and S1P 3 receptor activation (Sukocheva et al. 2006) .
All the three mammogenic agonists cause not only SK-1 activation but also increased proliferation and migration of MCF7 cells and these cell responses depend critically on SK-1, but not on SK-2. This is based on the findings that selective depletion of SK-1, but not SK-2, by siRNA transfections reduces MCF7 proliferation and migration in response to all three agonists (Figs 9 and 10 of this study; Döll et al. 2005) . Since all three agonists activate the SK-1 gene promoter, the question arises whether the same transcription factors are involved. SK-1 promoter analysis reveals the existence of several potential transcription factor-binding sites such as for Sp1, AP-1, AP-2, and AP-4. Recently, it was shown that PRL can activate AP-1 in breast cancer cells (Olazabal et al. 2000 , Gutzman et al. 2004b , and also EGF is a wellknown activator of c-Jun and c-Fos which are the relevant constituents forming AP-1 (Manfroid et al. 2005) . Moreover, E 2 can stimulate the recruitment of ERa and its cofactor p300 to the AP-1 site (Jeffy et al. 2005) . In addition, an interaction of PRL and E 2 was reported to cause an enhanced AP-1 activity by increasing MAPK/ ERK and c-Fos phosphorylation, and c-Fos promoter activity (Gutzman et al. 2004b , Gutzman 2005 .
Furthermore, a critical involvement of the STAT5 transcription factor in PRL-induced SK-1 upregulation and activation became evident from this study (Fig. 7A) . In this context, it has been extensively shown that PRL is an activator of the STAT5 transcription factor (Liu et al. 1995 , Hynes et al. 1997 and that various PRL-regulated genes contain a STAT-binding site in their promoter sequences . Sequence analysis of the SK-1 promoter indeed reveals such a putative STAT-binding site and future experiments will be needed to show whether this binding element is functional and able to bind STAT5.
Our data further suggest that especially the delayed second phase of SK-1 activation may be involved in the process of migration. This is stressed by the finding that either STAT5 depletion (Fig. 7) or incubation of cells in the presence of CHX (Fig. 5A) abolishes the delayed SK-1 activation as well as the migratory capacity of the cells (Fig. 11) , whereas the acute PRLtriggered SK-1 activation still occurs.
Interestingly, PRL-and also E 2 -stimulated SK-1 upregulation is prevented by the glucocorticoid dexamethasone. The mechanism of this suppressive effect is presently unclear. However, various studies have provided evidence that glucocorticoids can interact with transcription factors such as NFkB and thus prevent its nuclear translocation. Furthermore, glucocorticoids can induce the NFkB-inhibitory protein-a (IkB-a) and thereby prevent NFkB activity (Auphan et al. 1995) . Indeed, a potential NFkB DNAbinding element is found in the 5 0 -flanking region of the human SK-1 gene although the functionality of this element still needs to be proven. In vivo glucocorticoids not only act as immunosuppressive and antiinflammatory agents but are also effective in the treatment of leukemia as they act as inducers of apoptosis (Distelhorst 2002) . It is tempting to speculate that glucocorticoids promote apoptosis by suppressing SK-1 expression and activity and thereby reduce cellular S1P, which is considered not only a mitogenic factor but also an anti-apoptotic factor.
In summary, our data have shown that mammogenic hormones including PRL, estrogen, and EGF all induce SK-1 mRNA and protein expression via promoter activation which essentially contributes to increased cell proliferation and migration of breast cancer cells. Thus, the SK-1 may represent a novel and attractive pharmacological target to interfere with cancer cell growth and migration.
